Letters sent to healthcare professionals in December 2017

Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigo鈻�), and ERWINASE.

From:
Medicines and Healthcare products Regulatory Agency
Published
9 January 2018
Therapeutic area:
Cancer, Haematology and oncology, Neurology and Urology and nephrology

In December 2017, the following letters were sent to relevant healthcare professionals:

  • Cladribine (Litak and Leustat):

  • Radium-223-dichloride (Xofigo鈻�):

  • Vials of ERWINASE from batch 183a, 184a and 185a*

Article citation: Drug Safety Update volume 11 issue 6; January 2018: 6.

Updates to this page

Published 9 January 2018